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Abstract
Background: Chemoresistance is one of the most leading causes for tumor progression and recurrence of bladder
cancer. Reactive oxygen species (ROS) plays a key role in the chemosensitivity of cancer cells. In the present study,
emodin (1,3,8-trihydroxy-6-methylanthraquinone) was applied as a ROS generator in combination with cisplatin in
T24 and J82 human bladder cancer cells.
Methods: Cell viability and apoptosis rate of different treatment groups were detected by 3-(4,5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide (MTT) and flow cytometry (FCM). The expression of transporters was measured at both
the transcription and translation levels using PCR and western blotting. In vitro findings were confirmed by in vivo
experiments using tumor-bearing mice. The expression of multidrug resistance-associated protein 1 (MRP1) in tumour
tissue was measured using immunohistochemistry and side effects of the emodin/cisplatin co-treatment were
investigated by histological examination.
Results: Emodin increased the cellular ROS level and effectively enhanced the cisplatin-induced cytotoxicity of T24 and
J82 human bladder cancer cells through decreasing glutathione-cisplatin (GSH-cisplatin) conjugates. It blocked the
chemoresistance of T24 and J82 cells to cisplatin through suppressing the expression of MRP1. This effect was specific
in T24 and J82 cells but not in HCV-29 normal bladder epithelial cells. Consistent with in vitro experiments, emodin/
cisplatin co-treatment increased the cell apoptosis and repressed the MRP1 expression in xenograft tumors, and
without obvious systemic toxicity.
Conclusions: This study revealed that emodin could increase the cisplatin-induced cytotoxicity against T24 and J82
cells via elevating the cellular ROS level and downregulating MRP1 expression. We suggest that emodin could serve as
an effective adjuvant agent for the cisplatin-based chemotherapy of bladder cancer.
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Background
Bladder cancer is the second most commonly diagnosed
genitourinary neoplasm, with approximately 357,000 new
individuals occurring around the world and about 145,000
people dying from this disease each year [1, 2]. To date,
cisplatin-contained chemotherapy is commonly used in pa-
tients with advanced or metastatic bladder cancer. Several
meta-analysis revealed that cisplatin-based combination
chemotherapy could increase the overall survival rate just
by 5 ~ 11 % [3, 4]. However, chemoresistance is one of the
most leading causes for tumor progression and recurrence
of bladder cancer [1]. In non-muscle invasive bladder
cancer, 30–80 % of cases will recur and 1–45 % will pro-
gress to muscle invasion within 5 years [5]. Thus, it is ne-
cessary to reveal the mechanism of chemoresistance and
improve the sensitivity of chemotherapy in bladder cancer.
Reactive oxygen species (ROS), such as superoxide
free radical hydrogen peroxide or hydroxyl radicals,
refer to a series of intermediate products in the process
of oxidation-reduction system. The intracellular level of
ROS plays a key role in organic metabolism, survival
and physiological function [6, 7]. ROS has been found
to affect the chemosensitivity of cancer cells [6, 8]. It
has been reported that cancer cells can be induced to
apoptosis via increasing intracellular ROS generation by
anticancer drugs [9]. Zou et al. [10] verified that by in-
creasing intracellular ROS levels, Auranofin induced a
lethal endoplasmic reticulum stress response and mito-
chondrial dysfunction in gastric cancer cells and block-
age of ROS production reversed Auranofin-induced
endoplasmic reticulum stress, and mitochondrial path-
ways activation as well as apoptosis. Furthermore, others
also reported that increase of ROS generation not only
enhanced apoptosis in cancer cell lines, but also exerted
the assistant effect in vivo in clinical trials [11, 12]. Our
group has found that elevating ROS levels improved the
effect of platinum-based chemotherapy drugs against gall-
bladder cancer [13]. Thus, it is a potential therapeutic
strategy to enhance cytotoxicity of drugs by manipulating
oxidation-reduction status of cancer cells.
Multidrug resistance proteins are one of the most
important factors that cause chemotherapy resistance,
which can reduce the therapeutic efficacy and survival
for cancer patients [14]. ATP-binding cassette (ABC)
family is related to the multiple drug resistance (MDR),
which includes P-glycoprotein (P-gp) also named mul-
tiple drug resistance 1 (MDR1), multi-resistant related
protein family (MRPs) such as MRP1 and MRP2, and
breast cancer resistance protein (BCRP) also known as
ATP binding cassette subfamily G member 2 (ABCG2).
MDR is a serious obstacle in the management of bladder
cancer [15]. Therefore, inhibition of multidrug resistance
proteins is a potential way to improve the sensitivity of
chemotherapy.
Emodin (1,3,8-trihydroxy-6-methylanthraquinone) is a
kind of natural anthraquinone contained in the traditional
Chinese herbal medicines, especially from the root and
rhizome of Rhizoma and Radix families. Emodin plays
important roles in anti-inflammatory, antibacterial, diur-
etic, immunosuppressive and chemopreventive effects [13,
16, 17]. Furthermore, emodin is found to have anticancer
effect such as increasing cell apoptosis, cell death and
chemotherapeutic sensitization [13]. Emodin can effect-
ively increase levels of ROS and induce apoptosis in many
cancer cell lines [13, 16, 18, 19]. We previously reported
that emodin potentiated the anticancer effect on gallblad-
der cancer cells through inhibiting surviving [20]. We
further found that besides enhancing apoptosis in cancer
cell lines, emodin exerted the adjunctive treatment with
chemotherapeutics in vivo [13, 20].
Therefore, based on the above effects of emodin on
cancer cells, we hypothesized that emodin could act as
an effective agent in bladder cancer. Lin et al. [21] found
that emodin induced apoptosis in T24 human bladder
cancer cells via the activation of p53, p21, Fas/APO-1,
Bax and caspase-3. In this present study, we demon-
strated that emodin enhanced cisplatin-induced cytotox-
icity through ROS elevation and MRP1 downregulation
in T24 and J82 human bladder cancer cells.
Methods
Cell culture
The T24 human bladder cancer cells were supplied by
the Shanghai Institute of Cell Biology, Chinese Academy
of Sciences. The HCV-29 normal bladder epithelial cells
and J82 human bladder cancer cells were provided by
the Department of Cell Biology, Institutes of Medical
Sciences, Shanghai Jiao Tong University School of Medi-
cine. All cell lines were cultured in RPMI 1640 medium
(Invitrogen Corp, Carlsbad, CA, USA) supplemented
with 10 % fetal bovine serum at 37 °C in a humidified
atmosphere containing 5 % CO2. Emodin was obtained
from Sigma (St. Louis, MO, USA). Glutathione (GSH)
assay kit was purchased from Jiancheng Bioengineering
Institute (Nan Jing, China). Cisplatin was bought from
Qilu Pharmaceutical Co., Ltd. (Nan Jing, China). N-
acetylcysteine (NAC), the precursor of GSH, was pro-
vided by Sigma (St. Louis, MO, USA). For experiments
of 2.3, 2.4, 2.5, 2.6, and 2.7, T24 and HCV-29 cells were
treated with emodin (20 μM), cisplatin (1.5 μg/ml), or
emodin/cisplatin co-treatment, respectively. J82 cells
were treated with emodin (15 μM), cisplatin (1 μg/ml),
or emodin/cisplatin co-treatment, respectively.
Cell viability and apoptosis analysis
Cells were seeded in 96-well plates with 2.0 × 104 cells per
well. The cells were incubated with emodin for 24 h at dif-
ferent concentrations (0, 5, 10, 20, 30, 40, 50, 60, 70 μM)
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and chose the critical concentration (20 μM) treated with
cells for 0, 6, 12, 24, 48, 72, 96 h. The cells were incu-
bated with cisplatin for 24 h at different concentrations
(0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0 μg/ml). 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
(Sigma, St. Louis, MO, USA) assay was used to analyze
the cell viability as previously described [22]. Cells were
treated with drugs for 24 h and apoptotic rates were
assessed with flow cytometry using AnnexinV-fluorescein
isothiocyanate (AnnexinV-FITC)/propidium iodide (PI) kit
(BD Pharmingen, San Diego, CA, USA). Samples were pre-
pared according to the manufacturer’s instruction and ana-
lyzed by a flow cytometry (FCM) Calibur (Becton Dickson,
San Diego, CA, USA).
ROS measurement and GSH detection
2,7-Dichlorodihydrofluorescein diacetate (DCFH-DA)
method was used for intercellular ROS accumulation
[13]. After cells were treated with different regimens,
cells were further incubated with 10 mM DCFH-DA
for 15mins at 37 °C, with re-incubation of NAC (5 mM)
for 4 h, if used. After washed once with ice-cold phosphate
buffer saline (PBS), cells were harvested and kept on ice
for an immediate detection by FCM. GSH measurement
was conducted according to the instruction of assay kit
(Jiancheng Bioengineering Institute, Nan Jing, China). The
GSH content of the samples was detected as described by
Wang et al [19].
Western blotting
T24 cells were plated in 6 well plates and treated with
different regimens for 24 h before lysed in 100 μl of
sample solution as previously used by Huang et al [16].
Equal amounts of proteins were electrophoresed on
12 % SDS-polyacrylamide gel and transferred to a nitro-
cellulose membrane. The membrane was incubated for
1 h in blocking buffer (5 % low-fat milk powder in
blocking buffer containing) and then incubated with the
mouse antibody against human MDR1, MRP1, MRP2 and
ABCG2 (Abcam, Cambridge, UK) at 4 °C for overnight
and horseradish peroxidase-conjugated goat anti-mouse
immunoglobulin (Sigma, St. Louis, MO, USA) for 1 h be-
fore detected by an enhanced chemiluminescence system.
The details of antibodies used in this study were shown in
Additional file 1: Table S1.
qPCR and RT-PCR analysis
Total mRNA was extracted from treated cells using tri-
zol reagent (Invitrogen, Carlsbad, CA, USA) according
to the instruction of the manufacturer. The cDNA was
reverse-transcribed from 2 μg total RNA. β-actin was
used as an internal control. For qPCR, detection of
PCR products was performed on a Light Cycler system
(Roche Applied Science, Basel, Switzerland) using the
SYBR Green I kit (TaKaRa Biotechnology, Dalian, China),
according to the manufacturer’s instructions. Each sample
was done in triplicate. The expression levels of trans-
porters were normalized to β-actin mRNA expression.
The RT-PCR was performed as follows: denaturation for
5min at 95 °C, 30cycles of 95 °C for 30s, 55 °C for 45s and
72 °C for 30s, then extended for 10 min at 72 °C. The
sequences for β-actin sense and antisense primers were
shown in Additional file 2: Table S2.
MRP1 siRNA transfection
MRP1 siRNA oligonucleotides were transiently trans-
fected, using the Lipofectamine 2000 reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s
instructions with modifications as previously described
[23, 24]. In brief, cells were 50 % confluent at the time of
transfection. Oligomer-Lipofectamine® 2000 complexes
were added to each well containing cells and medium.
Mix gently by rocking the plate back and forth. After that,
cells were incubated at 37 °C in a CO2 incubator for 48 h
and medium were changed after 4–6 h. A nonspecific
siRNA was transfected as control, which was randomly
synthesized and did not correspond to any known gene in
the genome database. Forty-eight hours later, cells were
lysed for RT-PCR to verify the efficiency of silencing. After
that, T24 cells were treated by cisplatin and the rate of cell
apoptosis was detected by FCM described above. The
siRNA sequences for MRP1 and nonspecific control were
shown in Additional file 2: Table S2.
In vivo study in tumor-bearing mice
All the animal experiments were conducted according
to institutional guidelines for animal welfare and ani-
mal ethics were approved for all the experiments from
the animal committee of the Second Military Medical
University. 3 × 106 T24 cells were harvested, washed,
and resuspended in serum-free optimum medium and
then injected subcutaneously into 6-week old BALB/c-
nu/nu mice (n = 8 mice per group, purchased from
Shanghai Experimental Animal Center, Shanghai, China).
Three days after inoculation, the mice were intraperitone-
ally administered with PBS, emodin (50mg/kg), cisplatin
(1mg/kg), or emodin/cisplatin every two days. On day 18,
every mouse was sacrificed. After body weight measure-
ment, tumors were isolated, weighted and fixed in 4 %
paraformaldehyde (PFA). Hearts, livers and kidneys were
stained with Hematoxylin & Eosin to determine the sys-
temic toxicity as described by Li et al [22]. Terminal deox-
ynucleotidyl transferase(TdT)-mediated dUTP nick end
label (TUNEL) assay (Intergen, NY, USA) was performed
on paraformaldehyde-fixed and paraffin-embedded tumor
sections, using the methods described previously [19].
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Immunohistochemistry
MRP1 expression in tumor tissues was detected via im-
munohistochemistry. Briefly, all tumors were fixed in
4 % PFA, embedded in paraffin, and then cut into 5-μm
paraffin sections for immunohistochemistry. Deparaffi-
nized sections were dehydrated with alcohol series,
then incubated with a monoclonal antibody, (Abcam,
Cambridge, UK) at 4 °C overnight to detect MRP1 pro-
tein. The protein expression was defined as those show-
ing cytomembrane or/and cytoplasm brown staining.
Slides were then mounted using an aqueous solution
and photographed.
Statistical analysis
Statistical analyses were performed using SPSS Statis-
tics 17.0 software (SPSS Inc., Chicago, IL, USA) and re-
sults were considered statistically significant at p < 0.05
(two tailed). Data were shown as mean values ± S.D., and
some of the data were displayed in the form of chart. The
corresponding experimental figures were drawn using
GraphPad Prism v 5.0 software (Graphpad Software Inc,
La Jolla, CA, USA).
Results
Effects of emodin on T24, J82, and HCV-29 cell viability
To investigate the effects of emodin on cell viability,
T24 and J82 human bladder cancer cells, and HCV-29
normal bladder epithelial cells were treated with differ-
ent concentrations of emodin and at different times.
Our data showed that emodin killed T24 and J82 cells
in the dose-dependent and time-dependent manner,
and it was less toxic to HCV-29 cells. The concentra-
tion of 20 and 15 μM was selected as appropriate doses
for investigating chemotherapeutic sensitivity of T24
and J82 cells at 24 h, respectively (Fig. 1).
Effects of emodin co-treated with cisplatin on T24 and
J82 cells viability
According to the cell viability test (Additional file 3:
Figure S1 and Additional file 4: Figure S2), the cisplatin
concentration of 1.5 μg/ml was selected as an appropri-
ate dose for investigating chemotherapeutic sensitivity
at 24 h for T24 cells, and 1 μg/ml for J82 cells. As shown
in Fig. 2a, compared with cisplatin or emodin treatment
alone, emodin/cisplatin co-treatment could effectively kill
T24 and J82 cells. While after pre-treated with NAC, the
most commonly used precursor of GSH, for 2 h, the cell
viability of T24 and J82 cells could be largely reversed.
However, no significant treatment effect was observed on
HCV-29 normal bladder epithelial cells. These results
suggested that emodin/cisplatin co-treatment selectively
killed cancer cells.
The apoptosis rate of T24 and J82 cells after treatment by
cisplatin and emodin
For T24 cells, the apoptotic rate of emodin/cisplatin
co-treated group was 51.12 % ± 4.21 %, while that was
10.52 % ± 0.83 % of cisplatin treated group and 3.69 %
± 1.04 % of emodin treated group. In contrast to the
cisplatin treated group, the apoptotic rate was 25.14 %
± 1.68 % of NAC treated group (Fig. 2b). The apoptosis
of J82 cells after treatment showed the similar trend as
T24 cells.
Detection of cellular ROS and GSH levels
We found that emodin could sharply elevate the cellular
ROS levels and depletion of GSH in T24 and J82 cells.
While NAC, the precursor of GSH, could effective gener-
ate GSH and eliminate ROS (Fig. 2c and d). However, em-
odin treatment only slightly elevated ROS levels in HCV-
29 normal bladder epithelial cells (Fig. 2c), which might be
Fig. 1 a Emodin killed T24 and J82 cells in a dose-dependent manner after 24 h treatment, and was less toxic to HCV-29 cells. b Emodin
killed T24 and J82 cells in a time-dependent manner, and was less toxic to HCV-29 cells. The emodin concentration is 20 μM for T24
cells, and 15 μM for J82 and HCV-29 cell. Columns, mean of three experiments; bars, S.D. *p < 0.05, experimental group compared with
the control group. Each experiment was repeated three times
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attributed to the complex and effective repair mechanisms
of redox system in normal bladder epithelial cells.
Expressions of transporters
We measured the mRNA expressions of MDR1, MRP1,
MRP2, ABCG2, CTR1, ATP7A, and ATP7B in T24 and
J82 bladder cancer cells in different groups. MRP1 ex-
pression could be down-regulated at both the transcrip-
tion level and translation level by emodin/cisplatin co-
treatment while MDR1, MRP2, ABCG2, CTR1, ATP7A,
and ATP7B did not change in groups (Fig. 3a, b and c).
The role of MRP1 in cisplatin cytotoxicity
We further verify the role of MRP1 in the sensitivity of
bladder cancer cells to cisplatin using MRP1 siRNA trans-
fection. As shown in Fig. 3d and e, after MRP1 silencing,
the rate of cisplatin-mediated apoptosis was 23.14 % ±
3.42 %, which was higher than that of the control group
(2.12 % ± 0.91 %), suggesting that MRP1 was responsible
for the blockade of cisplatin cytotoxicity.
Effects of emodin co-treated with cisplatin in vivo
As shown in Fig. 4a, b and c, mice treated with emodin
and cisplatin had significantly smaller tumors than those
from the other groups. In addition, no notable differ-
ences on the body weight loss were observed among
groups (Fig. 4d) and no obvious necrosis and abnormity
were observed in the sections of liver, kidney and heart
(Additional file 5: Figure S3). These results demonstrated
that emodin/cisplatin co-treatment can significantly sup-
press tumor growth in vivo with no distinct side effects.
TUNEL assay in xenograft tumors
Consistent with in vitro experiment, TUNEL assay
showed that emodin/cisplatin combination significantly
increased cell apoptosis in xenograft tumors (Fig. 5a).
Fig. 2 a Emodin enhanced the cisplatin-induced cytotoxicity to T24 and J82 human bladder cancer cells, but had little cytotoxicity on HCV-29
normal bladder epithelial cells. The cell viability of T24 cells could be reversed after pre-treatment by NAC for 2 h. b Emodin enhanced the
cisplatin-induced apoptosis of T24 and J82 human bladder cancer cells, and this effect could be reversed by NAC. c Emodin effectively enhanced
cellular ROS levels in T24 and J82 human bladder cancer cells, but only slightly elevated ROS levels in HCV-29 normal bladder epithelial cells. d
Emodin effectively depleted GSH in T24 and J82 cells. The emodin concentration is 20 μM for T24 cells, and 15 μM for J82 and HCV-29 cell. The
cisplatin concentration is 1.5 μg/ml for T24 cells, and 1 μg/ml for J82 and HCV-29 cell. Columns, mean of three experiments; bars, S.D. *p < 0.05,
experimental group compared with the control group; S.D. #p < 0.05, NAC treatment group compared with emodin/cisplatin co-treatment group.
Each experiment was repeated three times
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Emodin/cisplatin co-treatment group also had lower
MRP1 expression than the other groups (Fig. 5b).
Discussion
Clinical MDR of bladder cancer is caused by a group of
integral membrane proteins that transport chemothera-
peutics across the cell membrane. [14, 15]. Platinum
influx transporters include copper transporter receptor
1 (CTR1) and organic cation transporters. The ABC
membrane transport proteins work as drug efflux pumps to
decrease the intracellular concentration of anticancer drugs,
and it have been reported that increased levels of the drug
resistance were associated with adenosine triphosphate
ABC transporters. [25–27]. CTR2 and copper-transporting
P-type adenosine triphosphates (ATPase’s) have also been
founded to affect the MDR of cancer cells [14, 25, 27]. In
the present study, we investigated the expressions of
MDR1, MRP1, MRP2, CTR1, ATP7A, ATP7B, and ABCG2
in T24 and J82 bladder cancer cells treated with emodin
and cisplatin alone or in combination. Our results demon-
strated for the first time that MRP1 plays a key role in the
chemoresistance of human bladder cancer cells. GSH has
been reported to play an important role in MRP1-mediated
MDR [28, 29]. Currently, MRP1 is considered as an ATP-
dependent GSH conjugate transporter. Different from
MDR1, MRP1 phenotype cannot transport platinum
drugs without GSH [29, 30]. Its substrates include anionic
hydrophilic lipid compounds, especially GSH, glucuronic
acid and sulfate conjugations [28–30]. In high MRP1-
expressing cancer cells, conjugations of chemotherapeutic
Fig. 3 a Emodin/cisplatin co-treatment down-regulated the mRNA expression of MRP1, but had no effect on the MDR1, MRP2, ABCG2, CTR1,
ATP7A, and ATP7B expression in T24 cells. b Emodin/cisplatin co-treatment down-regulated the mRNA expression of MRP1, but had no effect on
the MDR1, MRP2, ABCG2, CTR1, ATP7A, and ATP7B expression in J82 cells. c Emodin/cisplatin co-treatment inhibited the protein expression of
MRP1 but had no effect on the MDR1, MRP2, and ABCG2 expression in T24 cells. After transfected with MRP1 siRNA (d), the rate of cisplatin-
mediated apoptosis reached 23.14 % ± 3.42 %, which was higher that of the control group (e). Each experiment was repeated three times
Li et al. BMC Cancer  (2016) 16:578 Page 6 of 10
drugs combining with GSH can be quickly excreted by
MRP1/GSH pump [19]. Cisplatin is one of the most
widely used chemotherapeutics [31]. In the present study,
we found that T24 and J82 cells were resistant to cisplatin,
but emodin can enhance the chemosensitivity of bladder
cancer cells to cisplatin by reducing GSH levels or down-
regulating the expression of MRP1.
Recently, researchers have found that chemotherapeutic
effects often depend on the ROS levels in cancer cells [13,
16, 18, 19]. Cancer cells that are sensitive to chemothera-
peutic drugs tend to have higher levels of intracellular
ROS, while those with lower levels often exhibit MDR
[16]. Thus, the sensitivity of tumor cells to chemothera-
peutic agents can be enhanced via selectively elevating
Fig. 4 a Mice treated with emodin/cisplatin had significantly smaller tumors than those in other group. b Transplanted tumors on day 18. c
Average weight of transplanted tumors. d Average body weight of tumor-bearing mice on day 18. Columns, mean; bars, S.D. #p < 0.05, emodin/
cisplatin co-treatment group compared with cisplatin group (n = 8)
Fig. 5 a Emodin/cisplatin co-treatment significantly increased cell apoptosis in xenograft tumors. In TUNEL assay of transplantation tissues, the
cytoplasmic tan and yellow staining represented positive signal for cell apoptosis, and the nucleus were stained by blue. (n = 8). b Emodin/cisplatin
co-treatment decreased the expression of MRP1 protein in xenograft tumors. In immunohistochemistry of transplantation tissues, the cytoplasmic tan
and yellow staining represented positive protein signal for MRP1 protein, and the nucleus were stained by blue. Scale bar: 60 μm (n = 8)
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levels of ROS in cancer cells [17, 21, 22]. Higher concen-
tration of cisplatin can elevate ROS levels in cancer cells
and induce cytotoxicity. However, in the present study, we
choose a relatively low concentration of cisplatin (1.5 μg/
ml), which could only slightly increase ROS levels without
significant cytotoxicity. A low-dose of emodin alone had
no significant inhibitory on cell viability to T24 and J82
cells, but could significantly increase the intracellular ROS
levels, and enhanced the cisplatin-induced cytotoxicity.
Although the emodin/cisplatin co-treatment could also
slightly elevate ROS levels in normal bladder epithelial
cells, no significant cytotoxicity was observed. This might
be attributed to the redox system in normal bladder epi-
thelial cells and effective self-repair mechanisms [32, 33].
Emodin is a well-studied ROS generating agent and
has shown anti-tumor effects including cell cycle ar-
rest, cell proliferation inhibition, apoptosis induction,
chemotherapy sensitization, anti-angiogenesis and in-
hibition of tumor metastasis [17, 21, 34]. Our study
showed that emodin can significantly enhance the effi-
cacy of cisplatin-based chemotherapy of bladder cancer
both in vitro and in vivo. As shown in Fig. 6, low dose
of emodin alone can increase the levels of intracellular
ROS and deplete the GSH, resulting in enhanced
cisplatin-induced cytotoxicity, while high dose of emo-
din can directly damage cancer cell DNA. Emodin also
blocked the chemoresistance of T24 and J82 cells to
cisplatin through MRP1 downregulation. It has been
reported that low concentrations of emodin do not
affect the viability of cancer cells, but can enhance the
pro-apoptosis of arsenic trioxide [18]. Low concentra-
tions of emodin have also been reported to elevate
ROS levels in many tumor cells, and enhanced their
sensitivity to many chemotherapeutics [16, 19]. Several
studies indicated that emodin has anticancer effects in
other types of cancer through other mechanisms [35].
In this study, we found that emodin did not have significant
systemic toxicity in animals, or cytotoxicity to human nor-
mal bladder epithelial cells. Thus, it may be safe and effect-
ive as a synergetic chemotherapeutic agent. Although
emodin has not been employed in any clinical procedure
yet, it has broadened the therapeutic potential to cancer
patients, and may be tested in clinic in the near future.
There are some limitations of the present study. First,
cancer cell-based xenograft animal models are currently
considered with less reliability than orthotopic disease
models for the development and design of new therapies.
Further preclinical studies are required to confirm our
results. Second, although we showed no significant effect
of emodin/cisplatin administration on body weight and
histological findings of treated mice, it does not indicate
emodin has no toxicity. Long-term follow-up are needed
to adequately evaluate the toxicity of co-treatment.
Conclusions
In summary, this study revealed that emodin could in-
crease the cisplatin-induced cytotoxicity against T24 and
J82 cells via elevating the cellular ROS level and downreg-
ulating MRP1 expression. We suggest that emodin could
serve as an effective adjuvant agent for the cisplatin-based
chemotherapy of bladder cancer.
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after H&E stain. Scale bar: 60 μm (n = 8). (PPT 1365 kb)
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